Sector | Healthcare |
Industry | - |
Day Range | 21.35 | 21.72 |
52-Wk Range | - | - |
Last Close | 20.82 |
Mkt Cap (m) | 12,236.53 |
Dividend yield | 0.78 |
ISIN | ES0171996087 |
Volume | 209,174.00 |
Exchange Venue | XMAD |
Grifols SA is a pharmaceutical company. It primarily collects the liquid portion of human blood called plasma and then manufactures and sells plasma-derived products globally. It also operates diagnostics, hospital supplies, and raw materials businesses.
Price/Earning | 20.82 |
Price/Book | 2.67 |
Price/Sales | 2.65 |
P/CF | 13.21 |
Rev Growth (3 year avg) | - |
EPS Growth (3 year avg) | - |
Operating Margin % | - |
Net Margin % | - |
Return on Equity | - |
Debt/Equity | - |
en 23/04/2015 |
en 31/12/2019 |
Please refer to the below issuer website for further documents.
EUR | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
Revenue (m) | 3,934.56 | 4,049.83 | 4,318.07 | 4,486.72 | 5,098.69 | - |
Operating Income (m) | 970.37 | 939.41 | 1,003.34 | 994.12 | 1,122.39 | - |
Net Income (m) | 532.15 | 545.46 | 662.70 | 596.64 | 625.15 | - |
Basic EPS | 0.78 | 0.80 | 0.97 | 0.87 | 0.91 | - |
Avg. Diluted Shares Outstanding (m) | 685.66 | 684.17 | 684.24 | 684.71 | 685.12 | - |
EUR | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
Current Assets (m) | 3,089.47 | 3,122.51 | 2,945.32 | 3,483.25 | 5,362.18 | - |
Non Current Assets (m) | 6,512.24 | 7,007.26 | 7,974.95 | 8,993.80 | 10,180.43 | - |
Total Assets (m) | 9,601.72 | 10,129.77 | 10,920.26 | 12,477.05 | 15,542.61 | - |
Current Liabilities (m) | 1,053.01 | 1,071.76 | 977.99 | 1,257.32 | 1,366.56 | - |
Total Liabilities (m) | - | - | - | - | - | - |
Total Equity (m) | 3,296.20 | 3,721.48 | 3,629.08 | 4,225.55 | 4,822.12 | - |
EUR | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
Operating Cash Flows (m) | 742.78 | 553.28 | 841.75 | 737.43 | 568.93 | - |
Capital Expenditure (m) | -567.02 | -292.69 | -322.97 | -307.72 | -412.31 | - |